Opinion|Videos|November 20, 2026

Treatment Targets, Formulations, and the Future of Testosterone

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

In this episode, ‘Treatment Targets, Formulations, and the Future of Testosterone,’ the panelists explore audience questions on monitoring, fertility, and formulation choice before looking ahead to the next decade of care. Successful testosterone therapy is measured by how a man feels, not by any single number on a laboratory report. Mohit Khera, MD, MBA, MPH, prioritizes symptom improvement. When levels rise without benefit, he looks for mimicking conditions such as depression or hypothyroidism before adjusting the dose. Abraham Morgentaler, MD, FACS, is not alarmed by an occasional level above the normal range. He aims for physiologic replacement, however, and questions clinics that deliberately target very high levels.

Amy M. Pearlman, MD, notes that exogenous testosterone suppresses sperm production, and that alternatives are best tried before starting testosterone. Helen L. Bernie, DO, MPH, offers clomiphene or enclomiphene to many men, not only those concerned about fertility, because these oral agents stimulate the body’s own testosterone production.

On formulations, Khera frames the choice around cost, compliance, convenience, and concentration. Morgentaler highlights newer oral options for men who abandon injections. Pearlman and Bernie stress that the first formulation is simply a starting point, revisited as preferences, insurance coverage, and response evolve. The panel also notes emerging evidence that oral formulations may spare spermatogenesis, and that modern oral products avoid the liver concerns of older agents.

Looking ahead, Morgentaler said he hopes resistance within medicine fades. Bernie rejects telling men to lose weight before treatment, arguing that lifestyle change and therapy work best together. Khera cites trial evidence supporting that combined approach, and closes with a call for approved testosterone therapy for women.

For clinicians, the closing message is that testosterone therapy is a manageable, learnable tool that can meaningfully change patients’ lives. Thank you for watching this Urology Times webinar series on testosterone therapy in men’s health. To hear about upcoming video series, please subscribe to our enewsletter.


Related to this article